In Friday’s Wall Street session, 89bio Inc (NASDAQ:ETNB) shares traded at $10.41, up 8.21% from the previous session.
ETNB stock price is now 30.10% away from the 50-day moving average and 25.07% away from the 200-day moving average. The market capitalization of the company currently stands at $1.52B.
With the price target of $11, Goldman recently initiated with Neutral rating for 89bio Inc (NASDAQ: ETNB). On March 13, 2025, Citigroup recently initiated its ‘Buy’ rating on the stock quoting a target price of $25, while ‘Wolfe Research’ rates the stock as ‘Outperform’
In other news, Le-Nguyen Quoc, insider sold 15,329 shares of the company’s stock on Apr 15 ’25. The stock was sold for $91,208 at an average price of $5.95. Upon completion of the transaction, the insider now directly owns 328,323 shares in the company, valued at $3.42 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 15 ’25, Officer QUOC LE-NGUYEN bought 15,329 shares of the business’s stock. A total of $91,171 was incurred on buying the stock at an average price of $5.95. A total of 3.21% of the company’s stock is owned by insiders.
During the past 12 months, 89bio Inc has had a low of $4.16 and a high of $11.84. As of last week, the company has a debt-to-equity ratio of 0.06, a current ratio of 18.03, and a quick ratio of 18.03. The fifty day moving average price for ETNB is $8.0016 and a two-hundred day moving average price translates $8.323075 for the stock.
The latest earnings results from 89bio Inc (NASDAQ: ETNB) was released for 2025-03-31. The company reported revenue of $75.91 million for the quarter, compared to $57.28 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 32.53 percent.
